Lexaria Bioscience regains Nasdaq bid price compliance; warrant exercises yield $444,895

Lexaria Bioscience Corp.

Received Nasdaq letter on Nov 3, 2023 confirming cure of $1.00 minimum bid price deficiency after 11 consecutive days above $1.00 (Oct 19 - Nov 2).
Since Oct 24, 2023, exercised warrants for 468,279 shares at $0.95/share, generating gross proceeds of $444,865.
Pre-funded warrants exercised for 303,058 shares at $0.0001/share, generating gross proceeds of $30.31.
Total common shares outstanding after these exercises: 9,752,259.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.